Eterna Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Charles Cherington Boosts Stake in Ernexa Therapeutics to 37.9% Following Private Placement and Dividend
Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 37.9% of outstanding common stock through participation in a private placement and a dividend payment.
NASDAQ
SCHEDULE 13D/A: Ernexa Therapeutics Investor Boosts Stake to 32.8% Amidst $7.25 Million Private Placement
Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 32.8% through participation in a two-tranche private placement totaling approximately $7.25 million.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Charles Cherington Boosts Stake in Eterna Therapeutics to 32.38% Through Debt and Warrant Conversions
Charles Cherington, a significant investor, has increased his beneficial ownership in Eterna Therapeutics Inc. to 32.38% through a series of strategic debt and warrant conversions and exchanges.